

Ashkan A Shahbandi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9069411/publications.pdf>

Version: 2024-02-01

14
papers

425
citations

1478505

6
h-index

1720034

7
g-index

14
all docs

14
docs citations

14
times ranked

745
citing authors

#	ARTICLE	IF	CITATIONS
1	BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer. <i>Cell Death and Differentiation</i> , 2020, 27, 3097-3116.	11.2	70
2	TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines. <i>Trends in Cancer</i> , 2020, 6, 98-110.	7.4	81
3	Medical students's ability to diagnose common dermatologic conditions in skin of color. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 957-958.	1.2	53
4	Analysis of race and gender disparities in incidence-based mortality in patients diagnosed with thyroid cancer from 2000 to 2014.. <i>Journal of Clinical Oncology</i> , 2020, 38, e18570-e18570.	1.6	0
5	Chemotherapy-induced senescent cancer cells engulf other cells to enhance their survival. <i>Journal of Cell Biology</i> , 2019, 218, 3827-3844.	5.2	80
6	Analysis across multiple tumor types provides no evidence that mutant p53 exerts dominant negative activity. <i>Npj Precision Oncology</i> , 2019, 3, 1.	5.4	73
7	Nation-wide trends in mortality of patients with ocular and orbit melanoma: 2000 to 2014.. <i>Journal of Clinical Oncology</i> , 2019, 37, e21061-e21061.	1.6	0
8	Receptor Regulation in Taste: Can Diet Influence How We Perceive Foods?. <i>J</i> , 2018, 1, 106-115.	0.9	5
9	Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment. <i>Breast Cancer Research</i> , 2018, 20, 115.	5.0	63
10	cfDNA analysis of mCRPC patients expressing mutations in Wnt signaling.. <i>Journal of Clinical Oncology</i> , 2018, 36, 256-256.	1.6	0
11	cfDNA TP53 mutations with treatment history and disease progression in metastatic CRPC.. <i>Journal of Clinical Oncology</i> , 2018, 36, 263-263.	1.6	0
12	Cosegregation of cfDNA AR amplifications and mutations in relation to BRAF and MYC in CRPC.. <i>Journal of Clinical Oncology</i> , 2018, 36, 261-261.	1.6	0
13	Cell-free DNA (cfDNA) analysis and evaluation of BRAF amplifications and mutations in metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 255-255.	1.6	0
14	Abstract 3830: Novel small molecule translation inhibitors with safety and efficacy in triple negative breast cancer (TNBC) animal models. , 2012, , .		0